Home > Research > Publications & Outputs > Effects of long-term treatment with the neurole...

Links

Text available via DOI:

View graph of relations

Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. / Krzystanek, Marek; Bogus, Katarzyna; Pałasz, Artur et al.
In: Pharmacological reports : PR, Vol. 67, No. 5, 10.2015, p. 965-969.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Krzystanek M, Bogus K, Pałasz A, Krzystanek E, Worthington JJ, Wiaderkiewicz R. Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. Pharmacological reports : PR. 2015 Oct;67(5):965-969. Epub 2015 Feb 13. doi: 10.1016/j.pharep.2015.01.017

Author

Krzystanek, Marek ; Bogus, Katarzyna ; Pałasz, Artur et al. / Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. In: Pharmacological reports : PR. 2015 ; Vol. 67, No. 5. pp. 965-969.

Bibtex

@article{4b1ffd7fe7674c22bb2392e753c9b5e0,
title = "Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus",
abstract = "BACKGROUND: Antagonists of the N-methyl-d-aspartate receptor (NMDA-R) are associated with symptoms of schizophrenia, leading to the hypothesis that NMDA-R hypofunction leads to the pathogenesis of disease. We evaluated the long-term effect of neuroleptic administration on the NMDA subunits via immunohistochemical analysis.METHODS: Rats received olanzapine, clozapine and haloperidol before evaluation of the expression of the NR1, NR2A and NR2B subunit proteins in the hippocampal areas of the brain, via a densytometric analysis of immunoexpression in the rat hippocampus.RESULTS: All of the neuroleptics examined caused a decrease in the expression of the NR1 subunit, and thus, one can assume that both olanzapine, clozapine and haloperidol decreased the number of NMDA receptors in the CA1 and CA2 areas of the brain.CONCLUSIONS: A decrease in hippocampal glutamatergic signalling after long-term neuroleptic administration may cautiously explain the incomplete effectiveness of these drugs in the therapy of schizophrenia-related cognitive disturbances.",
author = "Marek Krzystanek and Katarzyna Bogus and Artur Pa{\l}asz and Ewa Krzystanek and Worthington, {John J.} and Ryszard Wiaderkiewicz",
note = "Copyright {\textcopyright} 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.",
year = "2015",
month = oct,
doi = "10.1016/j.pharep.2015.01.017",
language = "English",
volume = "67",
pages = "965--969",
journal = "Pharmacological reports : PR",
issn = "1734-1140",
publisher = "Polish Academy of Sciences Publishing House",
number = "5",

}

RIS

TY - JOUR

T1 - Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus

AU - Krzystanek, Marek

AU - Bogus, Katarzyna

AU - Pałasz, Artur

AU - Krzystanek, Ewa

AU - Worthington, John J.

AU - Wiaderkiewicz, Ryszard

N1 - Copyright © 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

PY - 2015/10

Y1 - 2015/10

N2 - BACKGROUND: Antagonists of the N-methyl-d-aspartate receptor (NMDA-R) are associated with symptoms of schizophrenia, leading to the hypothesis that NMDA-R hypofunction leads to the pathogenesis of disease. We evaluated the long-term effect of neuroleptic administration on the NMDA subunits via immunohistochemical analysis.METHODS: Rats received olanzapine, clozapine and haloperidol before evaluation of the expression of the NR1, NR2A and NR2B subunit proteins in the hippocampal areas of the brain, via a densytometric analysis of immunoexpression in the rat hippocampus.RESULTS: All of the neuroleptics examined caused a decrease in the expression of the NR1 subunit, and thus, one can assume that both olanzapine, clozapine and haloperidol decreased the number of NMDA receptors in the CA1 and CA2 areas of the brain.CONCLUSIONS: A decrease in hippocampal glutamatergic signalling after long-term neuroleptic administration may cautiously explain the incomplete effectiveness of these drugs in the therapy of schizophrenia-related cognitive disturbances.

AB - BACKGROUND: Antagonists of the N-methyl-d-aspartate receptor (NMDA-R) are associated with symptoms of schizophrenia, leading to the hypothesis that NMDA-R hypofunction leads to the pathogenesis of disease. We evaluated the long-term effect of neuroleptic administration on the NMDA subunits via immunohistochemical analysis.METHODS: Rats received olanzapine, clozapine and haloperidol before evaluation of the expression of the NR1, NR2A and NR2B subunit proteins in the hippocampal areas of the brain, via a densytometric analysis of immunoexpression in the rat hippocampus.RESULTS: All of the neuroleptics examined caused a decrease in the expression of the NR1 subunit, and thus, one can assume that both olanzapine, clozapine and haloperidol decreased the number of NMDA receptors in the CA1 and CA2 areas of the brain.CONCLUSIONS: A decrease in hippocampal glutamatergic signalling after long-term neuroleptic administration may cautiously explain the incomplete effectiveness of these drugs in the therapy of schizophrenia-related cognitive disturbances.

U2 - 10.1016/j.pharep.2015.01.017

DO - 10.1016/j.pharep.2015.01.017

M3 - Journal article

C2 - 26398392

VL - 67

SP - 965

EP - 969

JO - Pharmacological reports : PR

JF - Pharmacological reports : PR

SN - 1734-1140

IS - 5

ER -